Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in MyelomaByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,James Davis, PhD,Kristen Boykin, PharmD, BCOP, BCPSPublished: June 30th 2026 | Updated: June 30th 2026
Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational ChallengeByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,James Davis, PhD,Kristen Boykin, PharmD, BCOP, BCPSPublished: June 30th 2026 | Updated: June 30th 2026
Subcutaneous Isatuximab Gains Approval for MM in Japan Ahead of Anticipated FDA DecisionByRyu Kariyawasam-Chavez, Content AssociateJune 22nd 2026
Phase 3 MonumenTAL-3 Trial Demonstrates Significant Survival Benefit With Talquetamab-Based Regimens in Relapsed/Refractory Multiple MyelomaByRyu Kariyawasam-Chavez, Content AssociateJune 17th 2026
Tec-Dara: Match Made in Heaven or Double Trouble? ByMatthew M. Lei, PharmD, BCOP,Shahrier Hossain, PharmD, BCOP,Brooke Peters, PharmD, BCOP,E. Bridget Kim, PharmD, BCPS, BCOPJune 16th 2026